{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "Money and Business/Financial Desk", "lead_paragraph": "IN the days before his trip to New Orleans last March, Michael Laird could not stop talking about oysters. It had been a long time since Mr. Laird, a professor at the University of Wisconsin at Whitewater, had splurged on the squishy delight of oysters, and he could barely wait to slurp down more. The very idea made his students cringe, but Mr. Laird paid them no mind. Only a select few understood the allure. As soon as he returned, though, Mr. Laird had to call in sick. Within two days, what had felt like the flu had become bad enough to put him in intensive care. His blood pressure fell. One by one, his organs shut down. Mr. Laird died a day later.", "headline": {"main": "Business; Gulf Coast Oyster Farmers Try Self-Regulation"}, "abstract": "Leaders of Gulf Coast oyster industry drop their longtime opposition to strict measures to reduce Vibrio vulnificus infections because fear of deadly bacteria has caused prices to plummet and California to consider restricting sale of Gulf oysters in summer; under proposal being considered, states will have to cut illnesses by 60 percent in next seven years; if they fail, they will be required to adopt expensive pasteurization techniques or simply stop gathering oysters from May through September; photo (M)", "print_page": "5", "word_count": 1211, "_id": "4fd22e528eb7c8105d7bbff5", "snippet": "IN the days before his trip to New Orleans last March, Michael Laird could not stop talking about oysters. It had been a long time since Mr. Laird, a professor at the University of Wisconsin at Whitewater, had splurged on the squishy delight of...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2001/05/27/business/business-gulf-coast-oyster-farmers-try-self-regulation.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "glocations", "value": "MISSISSIPPI"}, {"name": "glocations", "value": "GULF OF MEXICO"}, {"name": "glocations", "value": "TEXAS"}, {"name": "glocations", "value": "FLORIDA"}, {"name": "glocations", "value": "LOUISIANA"}, {"name": "glocations", "value": "ALABAMA"}, {"name": "subject", "value": "VIBRIO VULNIFICUS (BACTERIA)"}, {"name": "subject", "value": "OYSTERS"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "REGULATION AND DEREGULATION OF INDUSTRY"}, {"name": "subject", "value": "FOOD CONTAMINATION AND POISONING"}, {"name": "subject", "value": "FISH AND OTHER MARINE LIFE"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Greg", "lastname": "WINTER"}], "original": "By GREG WINTER"}, "document_type": "article", "pub_date": "2001-05-27T00:00:00Z", "section_name": "Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "The return of Senate control to the Democrats after more than six years will have a profound effect on a variety of business issues pending in Congress, slowing some deregulatory measures that had been moving through Capitol Hill and sharply rearranging the legislative agenda. With the rise of the Democrats, industry hopes have dimmed significantly for new legislation on everything from further deregulation in the banking, energy and telecommunications industries to changes in the nation's tort law system in ways favorable to big business.", "headline": {"main": "Senate Switch Alters Outlook For Businesses"}, "abstract": "Return of Senate control to Democrats after more than six years will have profound effect on variety of business issues pending in Congress, slowing some deregulation measures that have been moving through Congress and sharply rearranging legislative agenda; industry hopes have dimmed significantly for new legislation on everything from further deregulation in banking, energy and telecommunications industries to changes in nation's tort law system in ways favorable to business; health care will come under purview of committee led by Sen Edward M Kennedy; drug makers face increasing likelihood that Senate will investigate pricing practices with renewed vigor and adopt patients' bill of rights measure that includes prescription benefits provisions opposed by industry; Mary Sheila Gall, whom Pres Bush chose to head Consumer Product Safety Commission, is expected to face greater scrutiny; Sen Paul S Sarbanes is becoming chairman of Banking Committee and is expected to shift panel's focus to consumer protection from deregulation; photo (M)", "print_page": "1", "word_count": 867, "_id": "4fd209d78eb7c8105d776014", "snippet": "The return of Senate control to the Democrats after more than six years will have a profound effect on a variety of business issues pending in Congress, slowing some deregulatory measures that had been moving through Capitol Hill and sharply...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2001/05/25/business/senate-switch-alters-outlook-for-businesses.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "KENNEDY, EDWARD M"}, {"name": "persons", "value": "GALL, MARY SHEILA"}, {"name": "persons", "value": "SARBANES, PAUL S"}, {"name": "persons", "value": "BUSH, GEORGE W"}, {"name": "glocations", "value": "UNITED STATES"}, {"name": "organizations", "value": "CONGRESS"}, {"name": "organizations", "value": "CONSUMER PRODUCT SAFETY COMMISSION"}, {"name": "organizations", "value": "SENATE"}, {"name": "subject", "value": "APPOINTMENTS AND EXECUTIVE CHANGES"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "PRICES (FARES, FEES AND RATES)"}, {"name": "subject", "value": "CONSUMER PROTECTION"}, {"name": "subject", "value": "LAW AND LEGISLATION"}, {"name": "subject", "value": "REGULATION AND DEREGULATION OF INDUSTRY"}, {"name": "subject", "value": "TELEPHONES AND TELECOMMUNICATIONS"}, {"name": "subject", "value": "LEGAL PROFESSION"}, {"name": "subject", "value": "UNITED STATES POLITICS AND GOVERNMENT"}, {"name": "subject", "value": "UNITED STATES ECONOMY"}, {"name": "subject", "value": "SUITS AND LITIGATION"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "ELECTRIC LIGHT AND POWER"}, {"name": "subject", "value": "BANKS AND BANKING"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Stephen", "lastname": "LABATON"}], "original": "By STEPHEN LABATON"}, "document_type": "article", "pub_date": "2001-05-25T00:00:00Z", "section_name": "Technology; Health; Business; Washington"}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "In a new report that is being met with a mixture of astonishment and sometimes disbelief, two Danish researchers say the placebo effect is a myth. The investigators analyzed 114 published studies involving about 7,500 patients with 40 different conditions. The report found no support for the common notion that, in general, about a third of patients will improve if they are given a dummy pill and told it is real.", "headline": {"main": "Placebo Effect Is More Myth Than Science, Study Says"}, "abstract": "New study concludes that placebo effect is myth; researchers hold patients only seem to improve after taking placebos because most diseases have uneven courses in which their severity waxes and wanes; finding challenges some beliefs about mind-body connection in healing; study was conducted by researchers at Univesity of Copenhagen and Nordic Cochran Center, international organization that reviews randomized clinical trials, and is published in New England Journal of Medicine (M)", "print_page": "20", "word_count": 1223, "_id": "4fd22ff88eb7c8105d7be58b", "snippet": "In a new report that is being met with a mixture of astonishment and sometimes disbelief, two Danish researchers say the placebo effect is a myth.     The investigators analyzed 114 published studies involving about 7,500 patients with 40 different...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2001/05/24/us/placebo-effect-is-more-myth-than-science-study-says.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "UNIVERSITY OF COPENHAGEN"}, {"name": "organizations", "value": "NORDIC COCHRAN CENTER"}, {"name": "organizations", "value": "NEW ENGLAND JOURNAL OF MEDICINE"}, {"name": "subject", "value": "PLACEBOS"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "RESEARCH"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Gina", "lastname": "KOLATA"}], "original": "By GINA KOLATA"}, "document_type": "article", "pub_date": "2001-05-24T00:00:00Z", "section_name": "Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "Doctors are beginning to worry that Vioxx and Celebrex, two wildly popular arthritis drugs, may not be as safe as they were initially believed to be. Research presented to the Food and Drug Administration earlier this year showed that patients taking Vioxx, a Merck & Company drug, had a higher, but still relatively low, risk of heart attacks than patients taking an older pain reliever. The study received little public attention at the time, but the F.D.A. is considering whether to add information on possible cardiovascular side effects to both drugs' labels.", "headline": {"main": "Doubts Are Raised on the Safety of 2 Popular Arthritis Drugs"}, "abstract": "Doctors are beginning to worry Vioxx and Celebrex, popular arthritis drugs, may not be as safe as they were initially believed to be; research presented Food and Drug Administration earlier this year showed that patients taking Merck & Co's drug Vioxx had higher, but still relatively low, risk of heart attracks than patients taking older pain reliever; study received little public attention at time, but FDA is considering whether to add information on possible cardiovascular side effects to both drugs' labels; Wall Street is becoming aware of possible problems, with at least one analyst warning that problem could particularly affect Merck; Celebrex is Pharmacia's biggest-selling drug, generating sales of $2.3 billion in 12 months ending in March; Pfizer Inc co-markets Celebrex with Pharmacia; Merck sold $1.7 billion of Vioxx in same period; study sponsored by Merck last year showed that patients taking Vioxx had four times risk of heart attacks of patients taking naproxen, which is sold both generically and under brand names Naprosyn or Aleve (M)", "print_page": "1", "word_count": 1084, "_id": "4fd249eb8eb7c8105d7e7901", "snippet": "Doctors are beginning to worry that Vioxx and Celebrex, two wildly popular arthritis drugs, may not be as safe as they were initially believed to be.    Research presented to the Food and Drug Administration earlier this year showed that patients...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2001/05/22/business/doubts-are-raised-on-the-safety-of-2-popular-arthritis-drugs.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "PHARMACIA CORP"}, {"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "organizations", "value": "PFIZER INC"}, {"name": "organizations", "value": "MERCK & CO"}, {"name": "subject", "value": "HEART"}, {"name": "subject", "value": "SALES"}, {"name": "subject", "value": "GENERIC AND BRAND NAME PRODUCTS"}, {"name": "subject", "value": "ALEVE (DRUG)"}, {"name": "subject", "value": "CELEBREX (DRUG)"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "ARTHRITIS AND RHEUMATISM"}, {"name": "subject", "value": "LABELING AND LABELS"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "NAPROSYN (DRUG)"}, {"name": "subject", "value": "NAPROXEN (DRUG)"}, {"name": "subject", "value": "VIOXX (DRUG)"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Melody", "lastname": "PETERSEN"}], "original": "By MELODY PETERSEN"}, "document_type": "article", "pub_date": "2001-05-22T00:00:00Z", "section_name": "Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "Health & Fitness", "lead_paragraph": "Put on your reading glasses or use a magnifying glass and take a look at the ingredients list on your skin care products. Do you see words like glycolic acid, alpha-hydroxyoctanoic acid, hydroxycaprylic acid, glycomer in crosslinked fatty acids alpha nutrium or even mixed fruit acid? Do you know what they mean, why they are there and whether they are safe to slather on your skin?", "headline": {"main": "Time to Review Your Cosmetics, Under Bright Light", "kicker": "PERSONAL HEALTH"}, "abstract": "Jane E Brody Personal Health column on health hazards of many cosmetics; notes informative new Web site on cosmetics produced by Food and Drug Administration lists any number of compounds that could, in some cases, cause more skin problems than they cure; examples cited; photo (M)", "print_page": "5", "word_count": 1176, "_id": "4fd2593e8eb7c8105d805728", "snippet": "Put on your reading glasses or use a magnifying glass and take a look at the ingredients list on your skin care products.    Do you see words like glycolic acid, alpha-hydroxyoctanoic acid, hydroxycaprylic acid, glycomer in crosslinked fatty acids...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2001/05/22/health/personal-health-time-to-review-your-cosmetics-under-bright-light.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "creative_works", "value": "PERSONAL HEALTH (TIMES COLUMN)"}, {"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "subject", "value": "SKIN"}, {"name": "subject", "value": "CONSUMER PROTECTION"}, {"name": "subject", "value": "COSMETICS AND TOILETRIES"}, {"name": "subject", "value": "COMPUTERS AND THE INTERNET"}], "byline": {"person": [{"firstname": "Jane", "middlename": "E.", "lastname": "BRODY", "rank": 1, "role": "reported", "organization": ""}], "original": "By JANE E. BRODY"}, "document_type": "article", "pub_date": "2001-05-22T00:00:00Z", "section_name": "Technology; Health"}], "meta": {"hits": 5, "offset": 0, "time": 67}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}